These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 26930407)

  • 41. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions.
    Birkenaes AB; Birkeland KI; Engh JA; Faerden A; Jonsdottir H; Ringen PA; Friis S; Opjordsmoen S; Andreassen OA
    J Clin Psychopharmacol; 2008 Apr; 28(2):132-7. PubMed ID: 18344722
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Frequency of abnormal correlation between leptin and the body mass index during first and second generation antipsychotic drug treatment.
    Peña R; Marquina D; Serrano A; Elfakih Y; de Baptista EA; Carrizo E; Fernández V; Valery L; Teneud L; Baptista T
    Schizophr Res; 2008 Dec; 106(2-3):315-9. PubMed ID: 18835519
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course.
    Gebhardt S; Haberhausen M; Heinzel-Gutenbrunner M; Gebhardt N; Remschmidt H; Krieg JC; Hebebrand J; Theisen FM
    J Psychiatr Res; 2009 Mar; 43(6):620-6. PubMed ID: 19110264
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The relationship of changes in leptin, neuropeptide Y and reproductive hormones to antipsychotic induced weight gain.
    Fitzgerald PB; Scaffidi A; Morris MJ; de Castella AR; Kulkarni J
    Hum Psychopharmacol; 2003 Oct; 18(7):551-7. PubMed ID: 14533137
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
    Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
    BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of naltrexone on body fat mass in olanzapine-treated schizophrenic or schizoaffective patients: a randomized double-blind placebo-controlled pilot study.
    Taveira TH; Wu WC; Tschibelu E; Borsook D; Simonson DC; Yamamoto R; Langleben DD; Swift R; Elman I
    J Psychopharmacol; 2014 Apr; 28(4):395-400. PubMed ID: 24218048
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder.
    Hanssens L; van Winkel R; Wampers M; Van Eyck D; Scheen A; Reginster JY; Collette J; Peuskens J; De Hert M
    Schizophr Res; 2008 Dec; 106(2-3):308-14. PubMed ID: 18930377
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.
    Wu RR; Zhao JP; Guo XF; He YQ; Fang MS; Guo WB; Chen JD; Li LH
    Am J Psychiatry; 2008 Mar; 165(3):352-8. PubMed ID: 18245179
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625.
    Liebig M; Gossel M; Pratt J; Black M; Haschke G; Elvert R; Juretschke HP; Neumann-Haefelin C; Kramer W; Herling AW
    Obesity (Silver Spring); 2010 Oct; 18(10):1952-8. PubMed ID: 20168311
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin.
    Baptista T; Sandia I; Lacruz A; Rangel N; de Mendoza S; Beaulieu S; Contreras Q; Galeazzi T; Vargas D
    Int Clin Psychopharmacol; 2007 Mar; 22(2):69-76. PubMed ID: 17293706
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A longitudinal study on the impact of antipsychotic treatment on serum leptin in schizophrenia.
    Venkatasubramanian G; Chittiprol S; Neelakantachar N; Shetty TK; Gangadhar BN
    Clin Neuropharmacol; 2010; 33(6):288-92. PubMed ID: 21060283
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Application of plasma levels of olanzapine and N-desmethyl-olanzapine to monitor metabolic parameters in patients with schizophrenia.
    Lu ML; Chen CH; Kuo PT; Lin CH; Wu TH
    Schizophr Res; 2018 Mar; 193():139-145. PubMed ID: 28720417
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Possible association between the -2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain.
    Kang SG; Lee HJ; Park YM; Choi JE; Han C; Kim YK; Kim SH; Lee MS; Joe SH; Jung IK; Kim L
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):160-3. PubMed ID: 17804136
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nizatidine for the treatment of patients with quetiapine-induced weight gain.
    Atmaca M; Kuloglu M; Tezcan E; Ustundag B; Kilic N
    Hum Psychopharmacol; 2004 Jan; 19(1):37-40. PubMed ID: 14716710
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of second generation antipsychotics on leptin and ghrelin.
    Esen-Danaci A; Sarandöl A; Taneli F; Yurtsever F; Ozlen N
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1434-8. PubMed ID: 18579280
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The lipid metabolism abnormality in patients administered with olanzapine].
    Amano T; Hosaka S; Takami H; Sugiyama C; Oda K; Morikawa R
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Nov; 32(5-6):257-61. PubMed ID: 23373312
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.
    Narula PK; Rehan HS; Unni KE; Gupta N
    Schizophr Res; 2010 May; 118(1-3):218-23. PubMed ID: 20207521
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis.
    Popa C; Netea MG; de Graaf J; van den Hoogen FH; Radstake TR; Toenhake-Dijkstra H; van Riel PL; van der Meer JW; Stalenhoef AF; Barrera P
    J Rheumatol; 2009 Apr; 36(4):724-30. PubMed ID: 19273452
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of long-term treatment with antipsychotics on serum leptin levels.
    Herrán A; García-Unzueta MT; Amado JA; de La Maza MT; Alvarez C; Vázquez-Barquero JL
    Br J Psychiatry; 2001 Jul; 179():59-62. PubMed ID: 11435270
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Olanzapine--high potency antipsychotic drug inducing significant weight gain: a case report].
    Marić N; Josifović-Kostić D; Vuković O; Britivić D; Jasović-Gasić M
    Srp Arh Celok Lek; 2008; 136(5-6):284-8. PubMed ID: 18792627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.